Indian maker of cough syrup linked to Uzbekistan deaths halts production | CNN Business

  • 📰 cnni
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 59%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

The Indian maker of a cough syrup linked to at least 18 deaths in Uzbekistan has halted production after an investigation by drug regulators, India’s health minister said Friday

. Uzbekistan’s health ministry said the cough syrup, Doc-1, manufactured by the Indian pharmaceutical company Marion Biotech, had contained ethylene glycol, a toxic solution. The Uzbek ministry said seven employees have been dismissed due to negligence and that all relevant documents have been given to law enforcement for an investigation. The ministry also said the cough syrup was incorrectly used by parents.

In a statement Tuesday, Uzbekistan said the Doc-1 Max syrup was incorrectly used by parents as an anti-cold remedy on their own or on the recommendation of pharmacy sellers and this resulted in respiratory distress in children who consumed the medication. The Uzbek health ministry said in its statement that the deceased children had taken 2.5-5ml of the drug at home for 2-7 days, which exceeds the standard dose of the drug for children, prior to being admitted to the hospital.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 326. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

Some say, when exported from India to Uzbekistan 'syrups' held for 30-40 days at the Commission border under bad conditions. They are investigating it right now. We'll see...

日本 最新ニュース, 日本 見出し